The mean decreases in fasting plasma glucose from baseline to endpoint were significantly greater for all three rGLP-@ dose groups than for the placebo group , with the greatest decrease occurring in the @ pkm dose group ( -@ mg/dl , s.d. @ , p = @ ) .